RadNet Reports Second Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA(1) and Revises Upwards 2026 Financial Guidance Ranges
StockNews.AIAug 9, 4:00 PM EDT1 source
Trading thesisImportance 9/10
RDNT should trade higher into H2 2026 on expanded imaging guidance and AI-enabled growth, with potential multiple expansion as ARR and JV activity scale.
AI summary
What happened and why it matters
RadNet posted a strong Q2 2026 with total revenue of $622.7M (+25% YoY) and record EBITDA levels, led by Imaging Center growth and a fast Digital Health ARR build to $105.5M. FDA clearance of DeepHealth breast ultrasound AI supports near-term rollout and potential cost savings, while a Boise JV with Saint Alphonsus expands RadNet’s health-system footprint. Management increased imaging-center guidance, signaling higher profit potential in H2 2026.
Imaging Center guidance raised: Total Net Revenue $2.37–$2.42B; Adjusted EBITDA $345–$358M; Free Cash Flow $115–$125M.
FDA clearance of DeepHealth breast ultrasound AI supports near-term revenue and cost-savings from rollout.
Boise, Idaho JV with Trinity Saint Alphonsus expands 5 centers; DeepHealth solutions deployable across sites.
ARR for Digital Health reached $105.5M; external customers comprise ~63% of Digital Health Revenue.
Sentiment rationale
Guidance upgrade plus AI rollout and expanded health-system partnerships improve both near-term visibility and long-term growth potential, supporting multiple expansion and higher cash-flow trajectory.
Key facts
01
Q2 2026 total revenue $622.7M, up 25% YoY; imaging center growth drives gains.
02
Digital Health ARR reached $105.5M; external revenue about 63% of Digital Health Revenue.
03
DeepHealth AI cleared by FDA for breast ultrasound; rollout planned by year-end.
04
RadNet lifts 2026 imaging center guidance: revenue, EBITDA, and free cash flow up.
05
Boise joint venture with Saint Alphonsus; 157 of 442 locations in health-system partnerships.
Earnings
Category: Earnings; RadNet’s release centers on quarterly results, raised 2026 guidance, and AI-enabled growth, with notable JV activity—fits earnings-driven corporate developments that can impact valuation.